logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
Gifu Kyoritsu University cover

Gifu Kyoritsu University

Scholars6
Papers14
Citations114
Related Papers (14)
Publication Date
delete
IgA-Enriched Phenotype Predicts Liver-Related Events in MASLD
errJournal of Hepatology
IF33
err2026-07-15
err0
PREAI
errTakefumi Kimura; Shun-ichi Wakabayashi; Takanobu Iwadare; Shohei Kondo; Taiki Okumura; Hiroyuki Kobayashi; Yuki Yamashita; Yuma Kamijo; Kaede Fujita; Tomoyuki Nakajima; Takuro Uchida; Tomoo Yamazaki; Mai Iwaya; Takeshi Uehara; Hidenori Toyoda; Takashi Kumada; Takeji Umemura; Naoki Tanaka
errShare
errSave
Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma
errHepatology International
IF6.1
err2026-06-12
err0
PREAI
errKazunari Tanaka; Kunihiko Tsuji; Atsushi Hiraoka; Toshifumi Tada; Kazuya Kariyama; Ei Itobayashi; Toru Ishikawa; Hidenori Toyoda; Yuichi Koshiyama; Takeshi Hatanaka; Satoru Kakizaki; Atsushi Naganuma; Tomomitsu Matono; Yoshihide Ueda; Hironori Tanaka; Jumpei Okamura; Hideyuki Tamai; Kenji Kuwaki; Fujimasa Tada; Hideko Ohama; Yuki Kanayama; Kazuhiro Nouso; Michitaka Imai; Shinichiro Nakamura; Soo Ki Kim; Takashi Kumada
errShare
errSave
Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline—A Step Towards Functional Cure or a Marginal Margin? Authors' Reply
errALIMENTARY PHARMACOLOGY & THERAPEUTICS
IF6.7
err2026-05-22
err0
errOAAI
errTakashi Kumada; Masanori Atsukawa; Taeang Arai; Hidenori Toyoda; Junko Tanaka
errShare
errSave
Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors? Authors' Reply
errALIMENTARY PHARMACOLOGY & THERAPEUTICS
IF6.7
err2026-05-12
err0
errOAAI
errTakashi Kumada; Hidenori Toyoda; Satoshi Yasuda; Yuichi Koshiyama; Takanori Ito; Tomoyuki Akita; Junko Tanaka
errShare
errSave
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma
errHepatology Research
IF3.4
err2026-05-11
err0
PREAI
errKazuya Kariyama; Kazuhiro Nouso; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Hidenori Toyoda; Satoshi Yasuda; Toshifumi Tada; Kazunari Tanaka; Kunihiko Tsuji; Ei Itobayashi; Akemi Tsutsui; Koichi Takaguchi; Michitaka Imai; Toru Ishikawa; Takeshi Hatanaka; Yuki Kanayama; Satoru Kakizaki; Atsushi Naganuma; Yoshihide Ueda; Tomomitsu Matono; Hideyuki Tamai; Junpei Okamura; Hironori Tanaka; Yutaka Yata; Akiko Wakuta; Masatoshi Kudo; Takashi Kumada
errShare
errSave
Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score-Matched Study Using Linear Mixed-Effects Models
errALIMENTARY PHARMACOLOGY & THERAPEUTICS
IF6.7
err2026-05-04
err0
PREAI
errTakashi Kumada; Masanori Atsukawa; Norio Itokawa; Taeang Arai; Hidenori Toyoda; Akihito Tsubota; Tsunamasa Watanabe; Makoto Chuma; Kentaro Matsuura; Atsushi Hiraoka; Toshifumi Tada; Koichi Takaguchi; Keizo Kato; Hiroshi Abe; Joji Tani; Toru Ishikawa; Chikara Ogawa; Toru Asano; Tsunekazu Oikawa; Yoshihiro Matsumoto; Tomoyuki Akita; Junko Tanaka
errShare
errSave
Diagnostic Impact of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Retrospective Study
errHepatology Research
IF3.4
err2026-05-01
err0
errOAAI
errTakashi Nishimura; Toshifumi Tada; Yasuaki Suzuki; Kento Imajo; Katsutoshi Sugimoto; Sadanobu Ogawa; Hidenori Toyoda; Tamami Abe; Hidekatsu Kuroda; Masashi Hirooka; Asako Nogami; Satoshi Oeda; Hirokazu Takahashi; Tomoyuki Akita; Reiichiro Kondo; Takuma Nakatsuka; Ryosuke Tateishi; Yoichi Hiasa; Yuichiro Eguchi; Atsushi Nakajima; Hirohisa Yano; Shigehiro Kokubu; Junko Tanaka; Fuminori Moriyasu; Masayoshi Kage; Takashi Kumada; Hiroko Iijima
errShare
errSave
Performance of risk models in predicting outcomes of atezolizumab and bevacizumab therapy
errJournal of Gastroenterology
IF5.5
err2026-02-05
err0
PREAI
errTakeshi Hatanaka; Satoru Kakizaki; Atsushi Naganuma; Atsushi Hiraoka; Toshifumi Tada; Takashi Kumada
errShare
errSave
Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma
errHepatology Communications
IF4.6
err2025-08-29
err0
errOAAI
errHatanaka, Takeshi; Shibuya, Kei; Kakizaki, Satoru; Hiraoka, Atsushi; Tada, Toshifumi; Kariyama, Kazuya; Itobayashi, Ei; Tsuji, Kunihiko; Ishikawa, Toru; Toyoda, Hidenori; Koshiyama, Yuichi; Naganuma, Atsushi; Miyasaka, Yuhei; Kanayama, Yuki; Tanaka, Kazunari; Tada, Fujimasa; Ohama, Hideko; Nouso, Kazuhiro; Nakamura, Shinichiro; Kumada, Takashi; Ohno, Tatsuya; On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group
errShare
errSave
Response to Letter to ‘Serum CRP in Durvalumab–Tremelimumab-Treated HCC: Expanding the Inflammatory Narrative’
errLiver International
IF5.2
err2025-08-26
err0
PREAI
errTakeshi Hatanaka; Yutaka Yata; Satoru Kakizaki; Takashi Kumada
errShare
errSave
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma
errJournal of Gastroenterology
IF5.5
err2025-08-20
err0
PREAI
errHideko Ohama; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Hideyuki Tamai; Shohei Komatsu; Fujimasa Tada; Shinichiro Nakamura; Yoshiko Nakamura; Teruki Miyake; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Kazunari Tanaka; Takanori Matsuura; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Hirayuki Enomoto; Kosuke Matsui; Masaki Kaibori; Takumi Fukumoto; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada
errShare
errSave
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
errHepatology Research
IF3.4
err2025-08-06
err0
PREAI
errTomomitsu Matono; Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Hiroki Nishikawa; Kazunari Tanaka; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Yuichi Koshiyama; Hidenori Toyoda; Chikara Ogawa; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Hidenao Noritake; Hideko Ohama; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Takashi Nishimura; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Tomoko Aoki; Hidekatsu Kuroda; Yutaka Yata; Hideyuki Tamai; Takanori Matsuura; Shohei Komatsu; Yoshihide Ueda; Yoshiko Nakamura; Osamu Yoshida; Kosuke Matsui; Shinichiro Nakamura; Hirayuki Enomoto; Masaki Kaibori; Takumi Fukumoto; Yoichi Hiasa; Masatoshi Kudo; the Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts From 48 Clinics in Japan (HCC 48) Group
errShare
errSave
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab
errLiver International
IF5.2
err2025-07-07
err0
PREAI
errTomomitsu Matono; Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi
errShare
errSave
Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
errHepatology Research
IF3.4
err2025-06-14
err0
PREAI
errTomomitsu Matono; Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi
errShare
errSave